Akeso Biopharma began enrollment for its multicenter AK117‑302 Phase 3 study in October 2024, evaluating their antibody in head & neck squamous cell carcinoma . https://www.datamintelligence.com/research-report/head-and-neck-cancer-pipeline-insights